Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers

blonca9
Sep 5, 2024
1 min read

CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and previews key P2b data that is currently scheduled for mid-2025.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight